Activins are secreted proteins members of the transforming growth factor-b family. They are involved in many biological responses including regulation of apoptosis, proliferation and differentiation of different cell types. Activins A, B and AB are highly expressed in adipose tissue, and in this review we will illustrate that activins have a role in several steps of physiological and pathological development of adipose tissue. Activin A has been shown to be a critical regulator of human adipocyte progenitor proliferation and a potent inhibitor of their differentiation. Activin A could also be a mediator of fibrosis observed in obese adipose tissue. Activin B/AB is proposed as a new adipokine having a role in energy balance and insulin insensitivity associated with obesity. Therefore, activin pathway could represent a potential therapeutic target both for controlling the size and the phenotype of the adipose precursor pool and for obesity-associated metabolic complications.
INTRODUCTION
Obesity adipose tissue is characterized by dysfunctional hypertrophic adipocytes, an increase in the proportion of human adipose progenitors, 1 immune cell infiltration with chronic inflammation 2, 3 and fibrosis. 4 The limitation of adipose tissue expansion, in part due to inhibition of adipocyte progenitor differentiation in an inflammatory microenvironment, can lead to fat accumulation in ectopic tissues resulting in lipotoxicity and metabolic disorders.
Adipocytes are renewed in physiological conditions. As mature adipocytes do not divide in vivo, regeneration of adipocytes depends on self-renewal of a pool of adipose progenitors that remains present during adult life and that can be recruited to form new fat cells. 5, 6 Many growth factors have been implicated in regulation of the size of progenitors in the rodent models. However, factors controlling self-renewal, that is, proliferation and differentiation, of human adipocyte progenitors are largely unknown. In this review, we will illustrate that activins have a role in several steps of physiological and pathological development of adipose tissue.
ACTIVINS, ACTIVIN RECEPTORS AND SIGNALING PATHWAYS
Activins are secreted proteins members of the transforming growth factor (TGF)-b family. They are expressed in various tissues where they have been shown to regulate various biological process including regulation of apoptosis, proliferation and differentiation of different cell types. 7 Activins form dimers composed of inhibin b subunits and to date four b subunits have been identified in mammals (named bA, bB, bC and bE). Therefore, activins exist in different dimeric configurations. Homodimers of bA or bB subunits, named activin A and activin B, respectively, and heterodimer of bA and bB, named activin AB, are highly expressed in adipocyte progenitors and in mature adipocytes (Figure 1) . Natural binding proteins for the TGF-b members exist and have an important role in the negative regulation of TGF-b signaling. For instance, follistatin is an extracellular glycoprotein that functions as an antagonist-binding protein neutralizing the bioactivity of activins. 8 --11 Activin signals are transmitted through two types of transmembrane serine/threonine kinase receptors, type I and type II activin receptors (ActRIIA or ActRIIB). Once activins bind to ActRIIA or ActRIIB, type I receptors are recruited to the ligand/ActRII complex and become phosphorylated. 12 Then, type I receptors activate the Smad pathway that recruit activators or repressors to regulate target genes. 13 It has been reported, that in addition to the canonical Smad pathway, other intracellular pathways, such as p38MAPK, ERK1/2 and JNK, can be activated by activins in a cell-specific manner. 14, 15 ACTIVIN A IS AN AUTOCRINE/PARACRINE REGULATOR OF HUMAN ADIPOCYTE PROGENITOR PROLIFERATION Activin A expression is correlated with the undifferentiated state of adipocyte progenitors isolated from omental, subcutaneous and mesenteric human white adipose tissues. 16 Functional investigations revealed that activin A is a critical regulator of human adipose-derived stem cell proliferation. Cell proliferation decreases when adipocyte progenitors are treated with an activin A-neutralizing antibody, showing the existence of a basal activin A autocrine/paracrine signaling pathway involved in undifferentiated human adipocyte progenitor cell number. Activin A supplementation enhances human adipose-derived stem cell proliferating through Smad2 pathway activation as reported by Zaragosi et al. 16 commented and illustrated by JK Sethi. 17 A weak activation of ERK1/2 upon addition of activin A has been observed. However, its functional significance has not been tested and inhibition of p38 MAPK has no effect on activin A-induced cell proliferation. 16 Inhibin bB subunit is weakly expressed in undifferentiated human adipocyte progenitors, suggesting that activins B/AB do not have an important role in their biology ( Figure 1 ). Collectively, these data show that activin A regulates the number of undifferentiated adipoctyte progenitors in an autocrine/paracrine manner and that this effect used Smad2-dependent mechanisms. These observations are consistent with the mitogenic effect of activin A/Smad pathway observed on 3T3-L1 mouse preadipose cell line and on C3H10T1/2 fibroblasts.
Activin A displays also a proliferative effect on some other cell types such as on fibroblast-like synoviocytes in rheumatid arthritis. In that case, activin A proliferative activity is partially inhibited by follistatin. 19 Human adipocyte progenitors secrete follistatin, but regulation of activin A/follistatin ratio and its role in proliferation remain to be investigated.
ACTIVINS IN ADIPOCYTE DIFFERENTIATION AND POSSIBLE ROLE IN OBESITY
Activin A has a negative autocrine/paracrine functional role in the early steps of human adipocyte progenitor differentiation. Activin A is secreted by human undifferentiated adipocyte progenitors and its level decreases markedly upon induction of adipocyte differentiation. Indeed, activin A downregulation is necessary for commitment toward the adipocyte lineage as supplementation with activin A during the initial stages of the adipocyte differentiation program inhibits formation of lipid-containing cells. In the opposite, inhibition of activin A pathway markedly promote adipocyte differentiation. As for the proliferative effect, the anti-adipogenic effects of activin A are mediated through Smad pathway. The anti-adipogenic effect of Smad2 pathway in human adipogenesis is consistent with its anti-adipogenic effects previously reported for human umbilical cord perivascular cells 20 and mouse 3T3-L1 preadipose cell line. 21 Together, these reports show the existence of an autocrine/paracrine loop comprising the activin A/Smad2 pathway that has a critical negative role on adipocyte differentiation of human adipocyte progenitors. Overexpression of C/EBPb prevents anti-adipogenic of activin A, 16 suggesting that activin A functions upstream or through direct inhibition of C/EBPb. The molecular mechanisms involved in inhibition of C/EBPb by activin A remain to be determined.
In contrast to activin A, activin B/AB is weakly expressed during the early steps of adipogenesis but is highly expressed in human mature adipocytes. Authors propose activin B/AB as a new adipokine having a role in energy balance and insulin insensitivity associated with obesity. 22, 23 Consistent with this hypothesis, it has been reported that activin B/AB inhibits lipolysis of 3T3-L1 preadipose cell line. 24 In addition, expression of activin B/AB is higher in adipose tissue of obese diabetic ob/ob mice than in non-obese mice. More importantly, inhibin bB expression in adipose tissue of ob/ob mouse is regulated upon administration of leptin. 25 Finally, it has been reported several years ago that expression of inhibin bB with spatiotemporal expression of inhibin bA leads to reduce the mass of adipose tissue, which contains small and immature adipocytes, and thus impairs insulin sensitivity. 26 In addition, the basal metabololic rates of these mice are elevated with upregulation of mitochondriogenesis. 27 It is interesting to note that expression of PAI-1, the expression of which is associated with insulin resistance, and of interleukin-6 are stimulated upon activin A treatment of human adipocyte progenitors. 16, 28 Therefore, increase activity of activins may lead to insulin resistance and inflammatory states. All these observations support the hypothesis that the different activin isoforms are regulators of the different steps of adipogenesis and could have a role in energy balance, insulin insensitivity associated with obesity and energy expenditure.
Expression of myostatin, another member belonging to TGF-b superfamily, is modulated in skeletal muscle and adipose tissue of obese ob/ob mice, and in wild-type mice in response to dietary obesity. 29 Inhibition of myostatin in mice leads to increase muscle mass, to reduce fat mass, and mutant mice are resistant to dietinduced obesity. 30 More recently, it has been shown that suppression of TGF-b/Smad3 pathway regulates the acquisition of brown fat features by white adipose tissue and protects mice from obesity and diabetes. 31 Altogether, these reports point out the emerging role of TGF-b superfamily members and Smad pathway in regulating adiposity, as recently reviewed by Zamani and Brown. 32 The role of follistatin in human adipogenesis has been recently evaluated. 33 Follistatin is secreted both from subcutaneous and visceral adipose tissues and the major source has been identified in the CD34 þ /CD31À fraction that contains adipocyte progenitors. The authors have also observed a decrease of follistatin expression in subcutaneous adipose tissue of obese patients compared with with non-obese controls that can be recovered by antiobesity intervention. Interestingly, in contrast to activin A, follistatin promotes adipogenesis in vitro. It is interesting to note that follistatin displays opposite effect that activins on adipogenesis and as predicted for the proliferative effect of activin A on adipocyte progenitors, it is likely that the the follistatin/activins ratio should have a critical role. Levels of this ratio in adipose tissue of healthy subjects and obese patients remain to be investigated.
REGULATORS OF ACTIVIN EXPRESSION
Obesity is associated with new macrophages that are recruited into adipose tissue and is accompanied by chronic low-grade inflammation in this tissue. 2, 3 Some studies report that the differentiation potential of human adipocyte progenitors, isolated from subcutaneous fat, is inversely correlated with obesity whereas the pool of precursors cells is positively correlated to body mass index. 1, 34, 35 Therefore, these results suggest that the obese microenvironment is capable of inducing proliferation of human adipocyte progenitors while inhibiting their differentiation. Concordantly, human adipose tissue-macrophage-secreted factors stimulate proliferation of human preadipocytes in vitro. 36, 37 Moreover, adipose tissue macrophages have been shown to inhibit adipogenesis of the progenitor CD34 þ / CD31 À cell population. 38 Interestingly, activin A levels are significantly increase in subcutaneous adipose tissue of obese subjects compared with lean ones and are upregulated by adipose tissue macrophagesecreted factors, 16 suggesting a functional link between adipose progenitor proliferation, inhibition of their differentiation and macrophages mediated by activin A. Adipose-tissue macrophagesecreted factors involved in the stimulation of activin A expression remain to be identified. However, interleukin-1b, tumor necrosis factor-a and TGF-b are potent candidates as previous studies have shown in other cell model, that activin A secretion is increased upon treatment with these cytokines. 39, 40 Therefore, immunoinflammatory cells that accumulate within adipose tissue with obesity might contribute to fat mass enlargement through paracrine effects on progenitor cells (Figure 2) . It is tempting to propose that the disappearance of macrophages, for instance as a consequence of dieting, and in consequence reduction of activin A levels in adipose tissue might be favorable to the formation of additional adipocytes from adipose progenitors upon ending dietary restriction. This is a situation reminiscent of the 'yoyo' Figure 1 . Schematic expression of activins in adipocyte progenitors and adipocytes. Activin A, which is a homodimer of Inhba subunits (black box), is highly expressed in adipocyte progenitors. In contrast, activin B and activin A/B, which are heterodimers of Inhba and Inhbb subunits (white box), are more expressed in mature adipocytes.
phenomenon. Activin A is also a critical mediator of inflammation (for a recent review see Phillips et al. 41 ) and it is interesting to note that dexamethasone, an anti-inflammatory molecule, downregulates activin A secretion from human adipocyte progenitors. 16 Inhibin bb is also negatively regulated by dexamethasone in murine adipocyte. 25 It is tempting to speculate that antiinflammatory steroids could both promote the formation of new adipocytes via inhibition of activin A secretion in adipocyte progenitors and reduce insulin resistance in existing adipocytes via inhibition of activin B/AB (Figure 2 ). However, it has been shown in the animal model, that dexamethasone treatment impairs glucose tolerance and is associated with perturbation of lipid metabolism. 42 In addition to its stimulating effect on expression of proinflammatory cytokines in macrophages, activin A is positioned as a profibrotic factor in adipose tissue of obese patients. 37 Therefore, a question that should be addressed is related to the phenotype of adipocyte progenitors under conditions leading to the increase activity of activin A? The possibility that over activity of activin A turns adipocyte progenitors into myofibroblasts, source of fibrosis observed in obese adipose tissue 4 is a possibility that remains to be analyzed in details. Induction of myofibroblast markers in human adipocyte progenitor populations upon activin A or TGF-b treatment support this hypothesis. 43 
CONCLUSIONS
In conclusions, activin A promotes proliferation of human adipocyte progenitors, with the possibility to induce their fibrotic phenotype in a pathological context. Excess levels of activin A block differentiation of adipocyte progenitors. This anti-adipogenic effect could participate to limit adipose tissue expandibility and as a consequence to deposition of fat to ectopic sites. 44 Therefore, blocking activin A in adipose tissue of obese patients could represent a potential therapeutic avenue for controlling the size and the phenotype of the adipose precursor pool in adipose tissue and obesity-associated metabolic complications. Activin pathway inhibitors have been shown to have potential medical applications. 45 It has been reported that injection of follistatin reduces inflammatory disease severity mediated by activin A in the mouse animal models. 46 Soluble ActRIIA receptor (ACE-011) is in phase I clinical trials for the treatment of bone diseases. 47 However, further studies to determine the activin A and follistatin circulating levels in lean subjects and in obese patients are required to better define the clinical role of activin A and to validate activin A as a secreted biomarker. 
